Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The effects of Valacyclovir (VAV) augmentation or placebo (PLA) as adjuncts to conventional
antipsychotic drug treatment will be evaluated among patients with schizophrenia who have
been exposed to herpes simplex virus type 1 (HSV-1). Hypothesis: Valacyclovir (VAV)
augmentation improves (a) cognitive and (b) overall function among Herpes Simples Virus 1
(HSV-1) exposed early course schizophrenia patients.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
Dr. Ram Manohar Lohia Hospital Stanley Medical Research Institute